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I NFECTIOUS complications following orthotopic liver 
transplantation (OLD remain the major cause of pa-
tient mortality and morbidi~yK Despite advances in techni-
cal and preservation management. these complications 
have not decreased significantly with present immunosup-
pression regimens. We have initiated the first human 
clinical trials of OL T under FK 506 immunosuppression. 
and report the infectious disease profile in this early 
experience. 
METHODS 
Only those patients undergoing primary OL T were enrolled in this 
pilot study and followed prospectively from the time of surgery to 
death or discharge. A comparable group of recent control patients 
receiving Cy A and undergoing primary OL T were computer· 
matched for age. diagnosis. and United Network for Organ 
Sharing criteria and are included for comparison. Due to the 
limited follow-up in the FK 506 group. a similar postoperative 
time interval was identified for the controls. allowing companson 
of infections occurring during the same time interval. 
Immunosuppression 
The study patients received an intravenous induction dose of FK 
506 at 0.15 mg;kg and I g methylprednIsolone at the time of 
surgery. fntravenou~ maintenance doses of FK ~MS at 0.075 m~Dkg 
twice a day were given until the patients were able to take an oral 
preparation of 0.15 mg:kg in two divided daily doses. A rapid dall~ 
taper from 1 g to 20 mg of methylprednisolone v. as given over the 
,>ubsequent 5 days. 
The control patient'> received an intravenous induction dose llf 
CyA at 3 mg kg. ,"hICh was maintained until an oral Jiet was 
resumed; the subsequent Josage was then regulated by Jail\ 
serum monitoring tll maintain thc:rapeutic CyA levds. A raplJ 
daily methylprednisolone taper from I g to 20 mg d was also used. 
Rejection episodes were treated with I g ·;taoiJ pulses or recycles 
with com'asion to OKT3 for persistent acute cellular n:jection. 
Definition of Infections 
We have previously reported and claSSified infections as severe 
and nonsevere. as shown in Table 1,1 Briefly. bacteremia Vl ere 
defined by the i,olation of staphylo.:occus. Calldida sp. or aerobic 
gram-negative rod, in at least one blood culture, Other pathogens 
required isolation of bacteria in two blond cultures or in one 
positive blood culture. and in a culture from a known site of 
infection. Wound infections required hea\'y grllVlth of a pathogen 
in the presence of erythema and purulent drainage at the im:ision. 
Peritonitis required growth of a pathogen from ascitic fluid and a 
neutrophil count of > 3()() polymorphonuclear cells. Cholangitis 
required isolation and heavy growth of a pathogen from bile. the 
presence of fever. and elevated liver function tests. Pneumonia 
required the new appearance of lung infiltrates on chest x-ray. 
onset of new respiratory symptoms and/or hypoxemia. and the 
isolation of pathogens from sputum. Clos/ridium difficile colitis 
required a new onset of diarrhea and the presence of C difficile 
toxin in Slool. 
Symptomatic cytomegalovirus tCMV) was defined as a febrile 
syndrome associated with viremia and/or the presence of virus in 
tissues (liver. lung. or gastrointestinal tract). confirmed by histol-
ogy. Candidiasis required a positive fungal blood culture and/or 
growth of Candida sp from a sterile site. 
Prophylaxis 
All patients received perioperative antibiotics consisting of ampi-
cillin and cefolaxime at 4 gld for 72 hours. Oral acyclovir. 200 mg 
twice daily. lrimethoprim-sulfamethoxazole. 80 mwTMP/400 SMZ 
daily. and mycostatin. 500.000 U 4 times a day. were given to all 
patients. 
Statistics 
All proportions were analyzed b~ \"'. 
RESULTS 
The characteristics of the patient population are shown in 
Table 2. The two groups are comparable in terms of 
demographics and follow-up. Of note is that no death in the 
FK S(lA group was related to infection. while both deaths in 
the ..:,·ntrol group were. A significantly higher incidence of 
overall infections was seen in the control group. as shown 
in Table 3 (P = O.OS). Although no significant ditferences 
were noted when bacterial or fungal infections were com-
pared. there was a striking difference (P = 0.(2) in those 
patients who developed symplllmatic C~ls infection. 
The only infections seen in the FK 506 group were 
bacterial and included two abdominal wound infections 
(EIII('/'ohac{t'I' clol/cae [one J. StaphylococclIs allrell,l' 
[one]) requiring simple drainage and antibiotics. cholangi-
tis (Strcptococcils .ll/ccillJlil due to an obstructing biliary 
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stent found at exploratory laparotomy in the early postop-
erative period. and peritonitis (S aureus) not requiring 
operative intervention. Thirteen infections were noted in 
11 control patients and included peritonitis (two), pneumo-
nia (two). candidiasis (two), C difficile colitis (two). and 
symptomatic CMV (five). 
No patient in the FK 506 group acquired a symptomatic 
CMV infection. compared with five in the control group. 
Nonsymptomatic CMV or simple viral shedding was seen 
in three FK 506 patients. Recovery of CMV in the urine of 
two seropositive patients suggested reactivation. while a 
positive blood buffy coat in one seronegative patient 
receiving a seropositive graft suggested the occurrence of 
a primary asymptomatic infection. All five symptomatic 
patients in the control group had received intense immu-
nosuppression with increased steroid pulse and azathio-
prine therapy; three were also given OKT3 for persistent 
rejection. Four seronegative patients in the FK 506 group 
received grafts from seropositive donors and none devel-
oped a symptomatic infection. while five of seven similar 
control patients became symptomatic «(MV hepatitis 
[fourl. (MV gastritis [one)). Three deaths were docu-
mented. The sole FK 506 death was a 55-year-old woman 
with primary biliary cirrhosis and asymptomatic primary 
pulmonary hypertension due to a sudden hemodynamic 
decompensation and myocardial infarction on the 14th 
postoperative day. The two control deaths occurred out-
side the follow-up time period and were due to pneumonia 
at 61 days in one patient and to progressive multifocal 
leukoencephalopathy at 248 days in the other. 
Table 2. Comparative Demographics of 20 Primary Liver Trans· 
plant Recipients of FK 506 and Their CyA-Treated Controls Fol· 
lowed for Less Than 62 Days 
FK 506 Control 
(n = 20) (n : 20) 
Male/female ratio 1218 1218 
Mean age (yr) 40.5 39.0 
Range (yr) 18-64 20-60 
Mean follow-up (d) 35.5 36.3 
Range (d) 14-62 24-62 
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Table 3. Frequency of Severe Infections In Two Matched 
Groups of Liver Recipients 
FK 506 Control 
(n : 20) (n = 20) 
Total patients 
Patients infected 4 11 P < .05 
Infection 
Bacterial 4 4 NS 
Fungal 0 o NS 
Viral 0 5 P< 0.02 
Infection-related death 0 0(2), 
• Two deaths. pneumonia at 61 days and progressive mulhlocalleukoenceph-
alopathy at 248 days. 
DISCUSSION 
Infections following liver transplantation remain the most 
serious complication during the postoperative period. In a 
previous study from our institution. 67% of 101 consecu-
tive patients undergoing primary OLT developed severe 
infections. with symptomatic CMV infections noted in 22 
patients (22%) and associated with five deaths. I 
This pilot study of patients receiving FK 506 is encour· 
aging in that the seemingly powerful immunosuppressant 
ability of the drug is not overshadowed by an increase in 
infectious complications. In fact. when compared with a 
similar control group receiving standard therapy and fol-
lowed during the same early postoperative time interval. 
there was a significantly lower incidence of overall infec-
tions. The FK 506 infections were bacterial and can also be 
seen in a nonimmunosuppressed population. The lack of a 
statistical difference between the bacterial and fungal 
groups suggests that viral infections made the difference. 
The most striking finding was the incidence of sympto-
matic (MV infection. It is well-known that such infections 
occur following increased immunosuppression. which is 
common to rejection therapy. The FK 506 patients had 
significantly fewer rejection episodes and thus received 
less immunosuppression overall. No FK 506 patient was 
given OKT3. which may prove to be the most imponant 
omission in the antirejection protocol. as its role in dissem-
ination of (MV infection has been reported. c ' Also. 
rejection in itself has been shown to enhance (MY infec-
tion in a murine modelK~ The simultaneou~ occurrence of 
(MV in patients with other severe bacterial and fungal 
infections has led some investigators to suggest that its 
mere occurrence is immunosuppressive. < We can only 
speculate that the elimination of (MV infections may 
decrease these other serious infections. We caution against 
firm conclusions regarding late infections. as the maximum 
length of follow-up in these patients is limited to 62 days. 
However. the diagnosis of (MV infection in the control 
patients was at a mean of 31.5 days. which was less than 
the 35-day mean follow-up of the four seronegative FK 506 
patients. Our data suggest that the use of FK 506 in the 
early posttransplant period is associated with modest in-
fectious complications. low monality. and no observed 
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symptomatic CMV. Longer follow-uP and careful evalua-
tion of these patients will be necessary. 
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